The aim of our study was to compare the olokizumab efficacy in methotrexate-resistant Russian patients, depending on the polymorphisms of the IL6, IL6R, HLA-DRB1/B, IL17A, IL23R, TNFAIP3, and TNFA, and 50 other RA candidate genes, to identify potential allelic variants with prognostic significance. This evidence concerns the gene TNFAIP3 and rheumatoid arthritis.